Rafferty Asset Management
ADAP

Rafferty Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Rafferty Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-217,123
Closed -$369K – 1139
2022
Q2 		$369K Sell
217,123
-318,991
-60% -$548K ﹤0.01% 853
2022
Q1 		$1.1M Sell
536,114
-70,649
-12% -$191K 0.01% 757
2021
Q4 		$2.27M Sell
606,763
-134,152
-18% -$611K 0.01% 610
2021
Q3 		$3.83M Sell
740,915
-78,200
-10% -$351K 0.03% 377
2021
Q2 		$3.49M Sell
819,115
-213,246
-21% -$1.04M 0.02% 460
2021
Q1 		$5.48M Buy
1,032,361
+883,301
+593% +$5.06M 0.04% 266
2020
Q4 		$803K Buy
+149,060
New +$810K 0.01% 570

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rafferty Asset Management's ADAP Position: Q3 2022 in Review

Rafferty Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 217,123 shares — an estimated $369K sold.

Rafferty Asset Management first reported a position in ADAP in Q4 2020 and held it in 7 quarters. The position peaked at $5.48M in Q1 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

  • Rafferty Asset Management reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 217,123 Adaptimmune Therapeutics shares in Q3 2022, an estimated $369K.
  • Rafferty Asset Management first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 7 quarters.
  • Rafferty Asset Management's Adaptimmune Therapeutics position peaked at $5.48M in Q1 2021.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.